ICCC vs. ADCT, ACRV, ACRS, AMRN, IPHA, FULC, OCGN, CYBN, IKT, and TLSA
Should you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include ADC Therapeutics (ADCT), Acrivon Therapeutics (ACRV), Aclaris Therapeutics (ACRS), Amarin (AMRN), Innate Pharma (IPHA), Fulcrum Therapeutics (FULC), Ocugen (OCGN), Cybin (CYBN), Inhibikase Therapeutics (IKT), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry.
ImmuCell vs.
ImmuCell (NASDAQ:ICCC) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation.
13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 6.6% of ImmuCell shares are owned by company insiders. Comparatively, 4.1% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
ADC Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 426.32%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe ADC Therapeutics is more favorable than ImmuCell.
ImmuCell has higher earnings, but lower revenue than ADC Therapeutics. ImmuCell is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
ImmuCell has a net margin of -15.99% compared to ADC Therapeutics' net margin of -300.00%. ADC Therapeutics' return on equity of 0.00% beat ImmuCell's return on equity.
ImmuCell received 61 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 68.18% of users gave ADC Therapeutics an outperform vote.
ImmuCell has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.
In the previous week, ADC Therapeutics had 3 more articles in the media than ImmuCell. MarketBeat recorded 4 mentions for ADC Therapeutics and 1 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.87 beat ADC Therapeutics' score of 0.57 indicating that ImmuCell is being referred to more favorably in the media.
Summary
ADC Therapeutics beats ImmuCell on 10 of the 18 factors compared between the two stocks.
Get ImmuCell News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuCell Competitors List
Related Companies and Tools
This page (NASDAQ:ICCC) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy ICCC Stock Free ICCC Stock Alerts